Loading patent…
AssigneesOklahoma Medical Research Foundation, Yale University
InventorsPeter J. Sims, Alfred L.M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
Estimating the term…
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
A transgenic non-human mammal all of whose nucleated cells contain a nucleotide sequence encoding human CD59, wherein CD59 is expressed on the surface of the mammal's cells capable of expressing human CD59, in an amount effective to inhibit complement mediated damage when the cells are exposed to human blood or serum and where the cells express at least 1.times.10.sup.3 CD59 molecules per cell.
Dependencies are inferred from the claim text.